Dog Rax had bone cancer, was given a cancer vaccine at the Medical Center for Animals, and seems to be all right. It is hopeful news in the development of a cancer vaccine for humans, says Arjan Griffioen, professor of Experimental Oncology at Amsterdam UMC. He has been working on the development of this vaccine for some time, he hopes it will eventually benefit humans as well.
The 10-year-old Malinois dog Rax had an aggressive form of bone cancer. The prognosis was poor, Rax would not live long. At the Medisch Centrum voor Dieren (MCD) in Amsterdam, the tumor was removed and Rax – as the first dog in the Netherlands – was vaccinated against bone cancer. After more than three months of treatment, Rax seems to be back to his old self. And although much more research is still needed, it is hopeful news.
Rax had osteosarcoma, a malignant bone tumor on his hip head. The average life expectancy in dogs with this type of cancer, without additional treatments, is around 70 days. The current option for treating an osteosarcoma is to surgically remove the tumor, possibly supplemented with chemotherapy. This extends life expectancy by an average of one year.
Development of cancer vaccine
The MCD recently began research on a new treatment: a cancer vaccine. The vaccine triggers an immune reaction against certain proteins that only occur in tumors. You could say that the vaccine tries to train immune cells to also attack cancer cells. In this case a tumor blood vessel-specific protein.
Professor Arjan Griffioen of Amsterdam UMC has been working on the development of this vaccine for some time. It had already been tested in preclinical studies and in two dogs with bladder cancer. This showed that this therapy works better than, for example, chemotherapy. Unlike chemotherapy, the vaccination has very few side effects. The vaccination targets the tumor blood vessels. Griffioen: “Without tumor blood vessels, the tumor cells cannot survive and the researchers saw that the tumor disappears or any metastases.”
Chance for Rax
Anne van Renssen, a veterinarian in the MCD’s Orthopedics Department, discussed the experimental treatment with Rax’s owners, and they gave their consent. “Rax is still so strong and sprightly, we wanted to give it a chance. The most important consideration was whether he would still have quality of life after the operation. Looking back, we made the right choice; he is his old self again,” says Mr. De Vries.
More research
In the near future the MCD wants to treat more dogs with an equally aggressive type of tumor with the cancer vaccine. Like Arjan Griffioen, the MCD hopes that this will contribute to a cancer vaccine that also works for humans.
In the Life Sciences & Health round, 14 researchers have been selected for the Faculty of Impact programme for two years of intensive and personal guidance in entrepreneurship, intellectual property and investment. Four Amsterdam based researchers have been selected as well: Anouk Post (VU), Olivier Lugier (UvA), Felix Paulußen (VU) and Ewelina Weglarz-Tomczak (UvA). A […]
NewsRapid Photonics receives funding from Innovatiefonds Noord-Holland for the development of an innovative production process of photonic chips with lithium niobate. Rapid Photonics B.V. is a spin-off of the Vrije Universiteit Amsterdam. Through the new convertible loan of €300,000, the company will be getting their technology market-ready to produce integrated photonic chips with lithium niobate, […]
NewsThe grant amounts available to both AMC and VUmc will of course be combined again, creating a budget of approximately € 4 million that will be divided over the best PPP-research proposals that we will receive from all of you. Deadline for the pre-application is May 24.
News